Pertussis Market

DelveInsight’s ‘Pertussis- Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Pertussis, historical and forecasted epidemiology as well as the Pertussis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China.

The Pertussis market report provides current prophylactic treatment practices, emerging vaccines, and market share of the individual vaccines, current and forecasted 7MM and China Pertussis market size from 2018 to 2030. The report also covers current Pertussis prophylactic treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, Spain, Italy, France, and United Kingdom)
• Japan
• China

Study Period: 2018–2030

Pertussis Disease Understanding and Treatment Algorithm

Pertussis Overview

Pertussis, literally meaning “a violent cough,” and also known as whooping cough, or “the cough of 100 days,” is an acute respiratory infection caused by Bordetella pertussis. First discovered in the Paris epidemic of 1578, pertussis is characterized by a paroxysmal cough lasting ≥2 weeks, an inspiratory whoop, posttussive emesis, and posttussive syncope.

Its common name, whooping cough, is derived from the sound caused by a partially closed glottis obstructing a forceful inspiration. Although pertussis is typically considered a childhood disease, infection rates in adults and adolescents have risen, currently accounting for more than half of all reported cases.

Bordetella pertussis, the causative organism, was discovered in 1906, and a vaccine was developed in the 1940s. Before the pertussis vaccine was developed, pertussis was a major cause of infant morbidity and mortality. Immunity wanes to 50% 12 years after completing a vaccination series. Immunocompromised persons can also contract Bordetella bronchiseptica, which typically affects animals and is commonly known as “a kennel cough.

Pertussis Diagnosis

The diagnosis is based on signs and symptoms and by culture, PCR, and serology. B. pertussis is transmitted by aerosols and infects the ciliated epithelium of the airways. There is no further dissemination of the infection, but bacterial toxins produced in the respiratory tract contribute to local and systemic disease pathogenesis. Despite several decades of research, there are still significant gaps in understanding the role and activity of B. pertussis virulence factors and the pathogenesis of pertussis disease, especially the severe disease in young infants. However, the development of new animal models in recent years and the possible implementation of human volunteer experiments soon provide the opportunity to increase the basic understanding of pertussis and hopefully to develop novel effective vaccines and therapeutics.

Pertussis Treatment

Prophylactic treatment for whooping cough depends on the patient’s age and how long the patient had the infection. If the patient’s whooping cough is severe, or baby is under 6 months old and has whooping cough, hospital treatment is usually needed. Immunization against pertussis is included on the US childhood immunization schedule as part of the combined DTaP shot. This vaccine is given in several doses, with the first recommended at two months of age and the last between age 4 and 6 years.

The Pertussis treatment aims to make the infection less serious and prevent spreading the disease to close contacts. The mainstay treatment of the condition includes the use of antibiotics. Erythromycin is the first-line treatment for pertussis. Azithromycin and clarithromycin are alternative treatments.

Complete immunization is important to prevent pertussis. The vaccine for pertussis is usually given with diphtheria and tetanus (often in combination also with poliomyelitis, H. influenzae and hepatitis B). Two kinds of acellular Vaccines that are mostly used to protect against pertussis in infants, children’s, and adults are Diphtheria, tetanus, and pertussis (DTaP) vaccines and Tetanus, diphtheria, and pertussis (Tdap) vaccines. It has been estimated that acellular vaccine is 71–85% effective, while the whole-cell vaccine is only 78% effective. The Food and Drug Administration (FDA) licensed 12 combination vaccines for use in the United States to help protect against diphtheria and tetanus. Nine of these vaccines also help protect against whooping cough. Some of the vaccines include protection against other diseases as well, including polio, Haemophilus influenzae type b disease, and hepatitis B.

The current US market for Pertussis is dominated by vaccines manufactured by Sanofi. Sanofi Pasteur is one of the key players in pediatric vaccines in both developed and emerging markets, with a broad portfolio of standalone and combination vaccines protecting against up to six diseases in a single injection. Another major key player in the market for pertussis vaccines is GlaxoSmithKline (GSK). Some of the pediatric and adult vaccines by Sanofi and GSK are Vaxelis, Adacel, Quadracel, Boostrix, Infanrix, Kinrix, and many more.

Pertussis Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Age-specific vaccine immunization rate in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China market from 2018 to 2030.

Key Findings

This section provides glimpse of the pertussis epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China.

• The total vaccine coverage population of Pertussis in the 7MM and China was 65,837,354 in 2020.
• The age-specific vaccine coverage case of Pertussis in the United States was estimated to be 20,058,055 in 2020.
• Among the EU5 countries, Germany had the highest vaccinations followed by France (2,650,337) and Italy (2,303,388). In contrast, the UK had the lowest vaccinations (1,795,059) in 2020.
• Japan accounted for 1,789,783 vaccinated population in 2020, and is estimated to decrease by 2030 owing to the decline in population.
• In China, the number of vaccinated population is expected to decline. The population was estimated to be 31,783,613 in 2020.
• The United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China – Pertussis Epidemiology
• The epidemiology segment also provides the Pertussis epidemiology data and findings across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan and China.

Pertussis Vaccine Chapters

The Vaccine chapter segment of the Pertussis report encloses the detailed analysis of Pertussis marketed vaccines and pipeline vaccines. It also helps to understand the Pertussis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included vaccines and the latest news and press releases.

Pertussis Marketed Vaccines

Adacel: Sanofi Pasteur

Adacel is a trivalent booster vaccine indicated for active immunization against pertussis, tetanus, and diphtheria. The vaccine is recommended from 4 years of age following primary immunization and is the first and only Tdap vaccine in the US. The vaccine is approved for a repeat dose in people 10–64 years of age 8 years or more after the first vaccination. It is available in 55 countries, including the US, Europe, Asia, and Latin America. It is administered as a single 0.5 mL intramuscular injection. For routine booster vaccination, the first dose of Adacel is administered 5 years or more after the last dose of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) series or 5 years or more after vaccination with Tetanus and Diphtheria Toxoids Adsorbed (Td). A second dose of Adacel may be administered 8 years or more after the first dose with Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Tdap). In June 2005, the US FDA approved the Adacel vaccine to address pertussis protection for people from 11 to 64 years of age. Adacel vaccine provides demonstrated immunogenicity against Pertussis tetanus and diphtheria and has a safety profile similar to that of the tetanus-diphtheria (Td) vaccine. In January 2019, the USFDA approved the expanded use of Adacel to include repeat vaccination to protect against pertussis, diphtheria, and tetanus.  Adacel is also the only Tdap vaccine available in a syringe made without natural rubber latex, which may help reduce risk to patients with an allergy.

Product details in the report…

Hexaxim/Hexyon/Hexacima: Sanofi Pasteur

Hexaxim (DTaP–IPV–HB–Hib) is a 6-in-1 pediatric vaccine indicated for primary and booster vaccination of infants and toddlers from 6 weeks of age against pertussis, tetanus, diphtheria, hepatitis B, poliomyelitis, and invasive diseases caused by Hemophilus influenza type b (Hib). The vaccine works by causing the body to produce its protection (antibodies) against bacteria and viruses.In 2019, the top 35 countries consumed 22 million hexavalent vaccines, representing 92% of the hexavalent vaccine global consumption. In April 2013, the vaccines division of Sanofi announced that the European Commission approved 6-in-1 pediatric vaccine Hexacima (DTaP-IPV-Hib-HepB vaccine) for primary and booster vaccination of infants from six weeks of age. Hexyon is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against pertussis (whooping cough), tetanus, diphtheria, Hepatitis B, poliomyelitis, and invasive infections caused by Haemophilus influenzae type b. The vaccine is commercialized under the brand name HexyonTM in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi.

Product details in the report…

Vaxelis: Sanofi Pasteur

Vaxelis is a PR5i hexavalent combination vaccine indicated for active immunization to prevent pertussis (whooping cough), diphtheria, tetanus, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b. Vaxelis was developed as part of a US-based partnership established in 1991 between Merck and Sanofi Pasteur and draws upon both companies experience in the development, manufacturing, and marketing of individual and combination vaccines. It includes antigens for pertussis (whooping cough), diphtheria, tetanus, and poliomyelitis from Sanofi Pasteur and antigens for Haemophilus influenzae type b and hepatitis B from Merck. In June 2021, Vaxelis developed as part of a US-based partnership between Merck and the global vaccines business unit of Sanofi, is now available in the US indicated for active immunization to help prevent pertussis, diphtheria, tetanus, poliomyelitis, hepatitis B, and invasive disease due to H. influenzae type b. In December 2018, US FDA has approved the Vaxelis vaccine for the treatment of acellular pertussis and other indications, which include Diphtheria, Tetanus Toxoid, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B for use in children from 6 weeks to 4 years of age (before the 5th birthday). In February 2016, the European Commission granted marketing authorization to Vaxelis (V419) for the treatment of pertussis with other indications, which include Diphtheria, Hepatitis B, poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b (Hib) for use in infants and toddlers from the age of 6 weeks.

Product details in the report…

Boostrix: Glaxosmithkline (GSK)

Boostrix is indicated for active booster immunization against tetanus, diphtheria, and pertussis in individuals aged 10 years and older. Boostrix is administered as a 0.5-mL intramuscular injection into the deltoid muscle of the upper arm. An initial dose of Boostrix is administered 5 years or more after the last dose of the Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) series or 5 years or more after a dose of Tetanus and Diphtheria Toxoids Adsorbed (Td). Boostrix is one of the vaccines routinely recommended in the US for immunization of pregnant women. There have been no reported safety concerns in the US with the use of the vaccine in pregnancy. There is no evidence of risk to the pregnant woman or unborn child with inactivated vaccines like Boostrix IPV. The licence for Boostrix IPV allows for its use in pregnancy when clearly needed, and when the possible benefits outweigh the possible risks. In the UK, Boostrix IPV is similar to the 4-in-1 vaccine – the pre-school booster that is routinely given to children before they start school. Also, Boostrix is given during pregnancy in the UK. In July 2011, the US FDA approved the Boostrix vaccine to prevent tetanus, diphtheria, and pertussis in people ages 65 and older.

Product details in the report…

Quadracel: Sanofi Pasteur

Quadracel [Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine] is a sterile, uniform, cloudy, and white to off-white suspension of acellular pertussis and diphtheria and tetanus toxoids vaccine adsorbed separately on aluminum phosphate combined with inactivated poliomyelitis vaccine types 1, 2 and 3 and suspended in water for injection. The acellular pertussis vaccine is composed of five purified pertussis antigens (PT, FHA, PRN, and FIM). A single dose of Quadracel vaccine is approved for use in children 4–6 years of age as a fifth dose in diphtheria, tetanus, pertussis vaccination (DTaP) series, and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series, in children who have received four doses of Pentacel or Daptacel vaccine. The vaccine provides these two vaccines in a single shot. In March 2015, the vaccines division of Sanofi announced that the US FDA had approved the use of Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP–IPV) vaccine for active immunization against pertussis, diphtheria, tetanus, and poliomyelitis in children 4–6 years of age.

Product details in the report…

Tetrabik/BK1310: Mitsubishi Tanabe pharma

Tetrabik is a combined prophylactic vaccine comprising a B. Pertussis protective antigen, adsorbed diphtheria toxoid, tetanus toxoid, and inactivated Savin types 1, 2, and 3 of poliovirus as active ingredients that prevent pertussis, diphtheria, acute poliomyelitis (polio), and tetanus. Tetrabik was developed in collaboration with the Research Foundation for Microbial Diseases of Osaka University and Biken. Tetrabik is administered as primary immunization series for children, which consist of three doses of 0.5 mL each given by subcutaneous injection at intervals of at least 3 weeks, and afterwards, the usual booster dose for children is a single 0.5 mL dose given by subcutaneous injection that is given at least 6 months after the primary immunization. In July 2012, the Ministry of Health, Labour and Welfare (MHLW) concluded that the Tetrabik may be approved. This result should be reported to the Pharmaceutical Affairs Department of the Pharmaceutical Affairs and Food Sanitation Council.

Product details in the report…

Pertussis Emerging Vaccines

BPZE1: ILiAD Biotechnologies

BPZE1 is a technologically advanced live attenuated pertussis vaccine that contains genetic modifications to eliminate, attenuate or inactivate three different B. pertussis toxins that are inactivated pertussis toxin, deleted dermonecrotic toxin, and marked reduction in Tracheal toxin to protect against Bordetella pertussis nasal infection (colonization) and active disease through the induction of broad and sustained mucosal and systemic immunity. BPZE1 is currently being developed as a booster vaccine, with future development investigating its application as a primary vaccination in infants. The BPZE1 strain was developed at the Institute Pasteur de Lille and Inserm by a team of scientists led by Dr. Camille Locht. It is the most advanced next-generation pertussis vaccine which has completed two Phase II clinical trials.

Product details in the report…

BK1310/MT-2355: Mitsubishi Tanabe pharma

DPT-IPV-Hib (BK1310/ MT-2355) vaccine is a 5-in-1 combination vaccine that protects against pertussis and other indications, including diphtheria, tetanus, and poliomyelitis, and prophylaxis of Hib infections in infants. This vaccine is co-developed with the Research Foundation for Microbial Diseases of Osaka University (Japan). The company has completed a Phase III trial in pertussis, and other indications include Diphtheria, Tetanus, Poliomyelitis, and Bacterial meningitis (In infants, in children, prevention) in Japan. The company plans to launch these five combined vaccines in Japan in FY2023.

Product details in the report…

SIIPL Tdap: Serum Institute/Bilthoven/VPM

SIIPL Tdap, manufactured by Serum Institute of India and Bilthoven Biologicals, is a combined vaccine for active immunization against tetanus, diphtheria and pertussis. The formulation contains reduced amounts of diphtheria and acellular pertussis antigens; therefore, it is indicated for booster immunization of adults, adolescents, and children. Vakzine Projekt Management GmbH (VPM) collaborates with the Serum Institute of India and Bilthoven Biologicals B.V. to develop the SIIPL Tdap vaccine. VPM is a development consulting firm for the biopharmaceutical industry. The vaccine has completed Phase III trial, and the Phase I trial was done in India to assess the safety and tolerability of SIIPL Tdap vaccine in healthy adult volunteers aged 18–45 years.

Product details in the report…

DTcP Infant and Booster: Cansino Bio

DTcP Infant vaccine is for infants (below 2 years old), addresses the weaker protection preventing pertussis after primary vaccination. DTcP Booster is a vaccine also being developed by the company that addresses the weaker protection preventing pertussis after primary vaccination, designed for children (4–6 years old). The vaccines are currently being developed in China, and they are in Phase II of development.

Product details in the report…

Pertussis Market Outlook

Pertussis, or whooping cough, is a contagious, infectious disease that mainly affects children and is caused by Bordetella pertussis. This disease spares no age group, though infants have the highest casualties. At the ground level, diagnosing pertussis remains a major challenge for clinicians. Variability in definitions, an evolving clinical spectrum from prior vaccination and lack of classic symptoms complicate the presentation. Early treatment of pertussis is essential. The earlier a person, especially an infant, starts treatment, the better. If a patient starts treatment for pertussis early in the course of illness, during the first 1–2 weeks before coughing paroxysms occur, symptoms may be lessened.

Treatment of pertussis is largely supportive, including oxygen, suctioning, hydration, and avoidance of respiratory irritants. Parenteral nutrition may be necessary as the disease tends to have a prolonged course. The treatment for whooping cough is usually antibiotics. The primary goal of antibiotic treatment is to decrease the carriage and spread of disease. Erythromycin (40–50 mg/kg per day, maximum 2 g per day, in 2–3 divided doses) is the first-line treatment for pertussis. Azithromycin (10 mg/kg per day on Day 1 followed by 5 mg/kg on Day 2–5) and clarithromycin (15 mg/kg per day in two divided doses) are alternative treatments. Trimethoprim-sulfamethoxazole (8 mg/kg per day of trimethoprim) has been used as an alternative in macrolide-allergic patients, but its efficacy has not been proven. The macrolides are not recommended for infants less than 4 weeks old for fear that this may lead to infantile hypertrophic pyloric stenosis.

The most important way to prevent pertussis is through complete immunization. The vaccine for pertussis is usually given with diphtheria and tetanus (often in combination also with poliomyelitis, Haemophilus influenza, and hepatitis B). Three vaccine formulations are available to protect against these diseases. DTaP vaccine is given to children 6 weeks to 6 years of age to protect them from illnesses. It is given at 2 months, 4 months, 6 months, 15–18 months, and 4–6 years. DTaP produces fewer side effects and is a safer version of an older vaccine called DTP, no longer used in the United States. Tdap vaccine, which contains a lower concentration of diphtheria and pertussis toxoids than DTaP, is licensed for people 10–64 years of age. It is given at 11–12 years. Adolescents and adults who have not yet received it should get a one-time dose of Tdap at the time of their next tetanus booster. A vaccine against tetanus and diphtheria only, Td, is recommended every 10 years after that (or sooner if patients have a wound). Td can be given to anyone ≥7 years.

DTap vaccines, such as Vaxelis, Quadracel, Infanrix, Daptacel, Tribik and others, are currently prescribed vaccines given in infants and children to prevent pertussis, diphtheria, tetanus, poliomyelitis, hepatitis B, and invasive disease due to H. influenzae type b. Tdap vaccines, such as Adacel (Repevax), and Boostrix are the currently prescribed vaccines given to adults for active immunization against pertussis, tetanus, and diphtheria.

Additionally, Sanofi Pasteur’s Vaxelis is a PR5i hexavalent combination vaccine indicated for active immunization to prevent pertussis, diphtheria, tetanus, poliomyelitis, hepatitis B, and invasive disease due to H. influenzae type b. Vaxelis was developed as part of a US-based partnership established in 1991 between Merck and Sanofi Pasteur and draws upon both companies experience in the development, manufacturing, and marketing of individual and combination vaccines. It includes antigens for pertussis, diphtheria, tetanus, poliomyelitis from Sanofi Pasteur, antigens for H. influenzae type b and hepatitis B from Merck. Vaxelis was approved by the USFDA in December 2018, becoming the first hexavalent vaccine to be approved in the US, and it became commercially available in the US in June 2021. It was approved in 2016 by the EMA and was commercially available in 2017.

Another vaccine Tribik/BK1301 is a combined inactivated vaccine that prevents pertussis, diphtheria, and tetanus. Tribik was developed in collaboration with the Research Foundation for Microbial Diseases of Osaka University and the Biken foundation. In February 2016, the MHLW approved Tribik, a vaccine with a new dosage indicated for the prevention of pertussis, diphtheria, and tetanus.

In March 2015, the vaccines division of Sanofi announced that the USFDA had approved the use of Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP–IPV) vaccine for active immunization against pertussis, diphtheria, tetanus, and poliomyelitis in children 4–6 years of age. This FDA approval was based on data from a pivotal multicenter, randomized, controlled, Phase III study designed to compare the safety and immunogenicity of Quadracel vaccine (DTaP-IPV) with Daptacel (DTaP) and IPOL (IPV) vaccines in children 4–6 years of age who were previously vaccinated with Daptacel or Pentacel (DTaP-IPV/Hib) vaccines. Results demonstrated that the Quadracel vaccine had similar safety and immunogenicity profiles compared to those of separately administered Daptacel and IPOL vaccines. Quadracel vaccine provides these two vaccines in a single shot. In January 2015, the report from the Centers for Disease Control (CDC) showed an 11% vaccination coverage drop off from the third to the fourth dose of DTaP and a 12% drop-off from the primary to full series of Haemophilus influenzae type b (Hib). Therefore to protect infants and children from life-threatening diseases, the CDC recommends children 4–6 years of age receive the fifth dose of the DTaP vaccine and the fourth dose of inactivated poliovirus (IPV) vaccine.

Adacel is a trivalent booster vaccine indicated for active immunization against pertussis, tetanus, and diphtheria. The vaccine is recommended from 4 years of age following primary immunization and is the first and only Tdap vaccine in the US. The vaccine is approved for a repeat dose in people 10–64 years of age 8 years or more after the first vaccination. It is available in 55 countries, including the US, Europe, Asia, and Latin America. In June 2005, USFDA approved the Adacel vaccine to address pertussis protection for people from 11 to 64 years of age. Adacel vaccine provides demonstrated immunogenicity against Pertussis tetanus and diphtheria and has a safety profile similar to that of the tetanus-diphtheria (Td) vaccine. In January 2019, US FDA approved the expanded use of Adacel to include repeat vaccination to protect against pertussis, diphtheria, and tetanus. Currently, the vaccine is not approved in Japan and China; however, it has completed Phase III trials in China and Japan to generate additional safety and immunogenicity data to support the product registration in China and Japan.

Boostrix (GSK) is a vaccine indicated for active booster immunization against pertussis, diphtheria, and tetanus in individuals aged 10 years and older. In the US., Boostrix was first approved for individuals aged 10 –18 in May 2005. Then, In December 2008, the vaccine was approved for use in adults 19 – 64 in the US. In July 2011, the US FDA approved an expanded age indication for Boostrix to include persons aged 65 years and older for the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. In 2020, the vaccine received approval in Europe for an expanded indication to include maternal immunization. Immunization of pregnant mothers will enable the mother’s immune system to make and transfer antibodies to help protect the unborn child against pertussis.

The developing pipeline of pertussis holds budding key players such as BPZE1 (ILiAD Biotechnologies), DPT-IPV-Hib (BK1310/ MT-2355) (Mitsubishi Tanabe Pharma Corporation), DTcP Booster (CanSinoBIO), SIIPL Tdap (Serum Institute/Bilthoven/VPM), and many more. These emerging vaccines, predicted to be launched during the forecast period, are likely to change the current market dynamics of pertussis prevention, thereby boosting the current market size of pertussis.

Key Findings

This section includes a glimpse of the Pertussis market.

• The market size of Pertussis in the seven major markets was USD 5,395 Million in 2020 and is expected to increase drastically owing to the launches of several potential emerging therapies during the forecast period (2021-2030).
• The United States accounted for the largest market size of Pertussis USD 2,435 million in 2020, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan
• Among the EU5 countries, Germany had the largest market size (USD 203 million) in 2020, while the UK and Spain had the smallest with USD 129 million. By 2030, the market size is anticipated to reach USD 218 million, USD 154 million and USD 153 million for Germany, UK and Spain respectively.
• In 2020, Japan accounted for a market size of USD 142 million, which is expected to decrease by 2030.
• In 2020, China accounted for a market size of USD 2,008 million, which is expected to decline by 2030.

This section provides the total Pertussis market size and market size by vaccines in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China.

Pertussis Vaccines Uptake

This section focusses on the rate of uptake of the potential vaccines recently launched in the Pertussis market or expected to get launched in the market during the study period 2018–2030. The analysis covers Pertussis market uptake by vaccines; patient uptake by vaccines; and sales of each vaccines.

This helps in understanding the vaccines with the most rapid uptake, reasons behind the maximal use of new vaccines and allow the comparison of the vaccines on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Pertussis Development Activities

The report provides insights into different prophylactic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted vaccines.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Pertussis emerging vaccines.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Pertussis market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Pertussis, explaining its causes, signs and symptoms, pathogenesis and currently available vaccines.
• Comprehensive insight has been provided into the Pertussis epidemiology and prophylactic treatment.
• Additionally, an all-inclusive account of both the current and emerging vaccines for Pertussis are provided, along with the assessment of new vaccines, which will have an impact on the current prophylactic treatment landscape.
• A detailed review of Pertussis market; historical and forecasted is included in the report, covering the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China vaccine outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China Pertussis market.

Report Highlights

• In the coming years, Pertussis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the vaccine manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Pertussis R&D. The vaccines under development are focused on novel approaches to treat/improve the disease condition.
• Delvelnsight has analysed the total age-specific and total vaccinated population of Pertussis.

Analyst Comments

• With high DTP vaccination rates in the 7MM and China among infants and children, and instances of pertussis re-emergence in the post-vaccination period, as well as an increased trend in yearly incidence cases in some countries, demand for DTP vaccinations, particularly new and improved vaccines, and remains high. Due to high immunization coverage, the market potential for new and improved vaccinations is enormous as older generation vaccines are expected to be phased out.
• Government funding on preventative healthcare and policy aid should be increased. There will almost certainly be an increase in the number of vaccines accessible on the open market, resulting in a significant increase in vaccine sales volume. Furthermore, new vaccinations are likely to become more widely available in the future as part of ongoing healthcare reform and the goal of obtaining maximum immunization coverage.
• There are a lot of competitive pressures in Europe and the United States since there are many vaccines currently being used. Pediarix and Pentacel, two well-known vaccines in the United States, are doing well. However, with the recent availability in the United States of a hexavalent vaccination called as Vaxelis, these vaccines are expected to be replaced in the coming years. When it comes to Tdap vaccinations or adult booster shots, Adacel/Repevax/Adacel-Polio and Boostrix are the only major alternatives in the EU-5 and the US. For GSK and Sanofi, life-time vaccination is unquestionably a growth sector and a development potential.
• Due to the impact of the COVID-19, stockpile movements, supply restrictions, and competitive pressures in the EU-5 and the US, there has been a pattern of vaccine sales declines. China.
• In the coming future, China will see the introduction of new vaccines for children, such as the DTcP primary and booster vaccines. In China, co-purified DTaP vaccines dominate the current DTP market in terms of sales volume, but DTcP vaccinations are projected to replace co-purified DTaP vaccines in China in the coming period. At present, Sanofi is only company present in China with their DTcP vaccine Pentaxim, in addition to the domestic key players for pertussis. Due to an issue with the supplier of a raw ingredient used in the formulation of Pentaxim for China, the business had supply difficulties for the vaccine in 2018.
• Daiichi Sankyo, Mitsubishi Tanabe Pharma Corporation, and KM Biologics supply pertussis vaccinations in Japan. However, there was a report that production of Daiichi Sankyo's Square Kids Subcutaneous Injection Syringe would be halted due to difficulties in manufacturing the undiluted solution. According to DelveInsight assessment, Mitsubishi is now leading the Japanese vaccination market with Tetrabik.

Pertussis Report Insights

• Patient Population
• Therapeutic Approaches
• Pertussis Pipeline Analysis
• Pertussis Market Size and Trends
• Market Opportunities
• Impact of upcoming Vaccines

Pertussis Report Key Strengths

• Ten Years Forecast
• The United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China Coverage
• Pertussis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Vaccines Uptake

Pertussis Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the Pertussis market share (%) distribution in 2018 and how it would look like in 2030?
• What would be the Pertussis total market size as well as market size by vaccines in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China during the forecast period (2021–2030)?
• What are the key findings pertaining to the market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China?
• At what CAGR, the Pertussis market is expected to grow at the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China level during the forecast period (2021–2030)?
• What would be the Pertussis market outlook in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China during the forecast period (2021–2030)?
• What would be the Pertussis market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of Pertussis?
• What is the historical Pertussis patient pool in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China?
• What would be the forecasted vaccinated pool of Pertussis at the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China level?
• What will be the growth opportunities in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China with respect to the patient population pertaining to Pertussis?
• At what CAGR the population is expected to grow in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China during the forecast period (2021–2030)?

Current Treatment Scenario, Marketed Vaccines and Emerging Vaccines:

• What are the current options for the prevention of Pertussis along with the approved vaccines?
• What are the current prophylactic treatment guidelines for the prevention of Pertussis in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China?
• What are the Pertussis marketed vaccines and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing vaccines for the prophylactic treatment of Pertussis?
• How many vaccines are developed by each company for the prophylactic treatment of Pertussis?
• How many emerging vaccines are in the mid-stage and late stage of development for the prophylactic treatment of Pertussis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pertussis vaccines?
• What are the recent novel vaccines, targets, mechanisms of action and technologies developed to overcome the limitation of existing vaccines?
• What are the clinical studies going on for Pertussis and their status?
• What are the key designations that have been granted for the emerging vaccines for Pertussis?
• What is the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China historical and forecasted market of Pertussis?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Pertussis.
• To understand the future market competition in the Pertussis market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Pertussis in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for Pertussismarket.
• To understand the future market competition in the Pertussis market.